Heiko Ullmann

Inhibition of Platelet Functions and Thrombosis through Selective or Nonselective Inhibition of the Platelet P2 Receptors with Increasing Doses of NF449 [4,4′,4″,4″′-(Carbonylbis(imino-5,1,3-benzenetriylbis-(carbonylimino)))tetrakis-benzene-1,3-disulfonic Acid Octasodium Salt]

J. Cazenave, C. Gachet, R. Evans, 2005, Journal of Pharmacology and Experimental Therapeutics.

Synthesis and Structure−Activity Relationships of Suramin-Derived P2Y11 Receptor Antagonists with Nanomolar Potency

G. Schmalzing, J. Boeynaems, M. Kassack, 2005 .

Structure-activity relationships of suramin and pyridoxal-5'-phosphate derivatives as P2 receptor antagonists.

M. Kassack, G. Lambrecht, M. Ganso, 2002, Current pharmaceutical design.

Use‐dependent inhibition of the skeletal muscle ryanodine receptor by the suramin analogue NF676

M. Hohenegger, Anton Karel, M. Kassack, 2005, British journal of pharmacology.

Structure-activity relationships of analogues of NF449 confirm NF449 as the most potent and selective known P2X1 receptor antagonist.

M. Kassack, G. Lambrecht, M. Ganso, 2004, European journal of medicinal chemistry.

The novel suramin analogue NF864 selectively blocks P2X1 receptors in human platelets with potency in the low nanomolar range

M. Kassack, G. Lambrecht, M. Mahaut-Smith, 2005, Naunyn-Schmiedeberg's Archives of Pharmacology.

NF449: a subnanomolar potency antagonist at recombinant rat P2X1 receptors

G. Schmalzing, M. Kassack, G. Lambrecht, 2001, Naunyn-Schmiedeberg's Archives of Pharmacology.

Profiling at recombinant homomeric and heteromeric rat P2X receptors identifies the suramin analogue NF449 as a highly potent P2X1 receptor antagonist

G. Schmalzing, M. Kassack, G. Lambrecht, 2005, Neuropharmacology.

Structure-activity relationships of analogues of NF449 confirm NF449 as the most potent and selective known P2X1 receptor antagonist.

M. Kassack, G. Lambrecht, M. Ganso, 2004, European journal of medicinal chemistry.